High Growth Tech Stocks To Watch In Europe July 2025
Top 10 High Growth Tech Companies In Europe
Name
Revenue Growth
Earnings Growth
Growth Rating
Intellego Technologies
28.42%
47.04%
★★★★★★
Shoper
14.28%
23.79%
★★★★★☆
KebNi
20.56%
94.46%
★★★★★★
Bonesupport Holding
23.98%
62.26%
★★★★★★
Lipigon Pharmaceuticals
104.89%
93.94%
★★★★★☆
Yubico
16.27%
23.90%
★★★★★☆
ContextVision
5.83%
39.78%
★★★★★☆
Aelis Farma
79.30%
106.93%
★★★★★☆
SyntheticMR
18.81%
47.40%
★★★★★☆
CD Projekt
33.57%
40.19%
★★★★★☆
Click here to see the full list of 52 stocks from our European High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Pharming Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pharming Group N.V. is a biopharmaceutical company that focuses on developing and commercializing protein replacement therapies and precision medicines for rare diseases across the United States, Europe, and other international markets, with a market cap of €596.08 million.
Operations: Pharming Group generates revenue primarily through its Recombinant Human C1 Esterase Inhibitor business, which accounts for $320.71 million. The company's focus is on providing treatments for rare diseases in various international markets.
Pharming Group N.V. is navigating a complex landscape with an 8.3% expected annual revenue growth, which, although modest compared to some high-growth sectors, outpaces the Dutch market's 7.3%. The company's commitment to innovation is underscored by its significant R&D efforts aimed at tackling rare diseases like APDS; this focus not only differentiates it within the biotech industry but also enhances its potential in a niche market. Recent announcements include the hosting of a webcast to discuss groundbreaking findings in immune disorders and an upgrade in revenue guidance for 2025 to USD 325-340 million, reflecting positive business momentum. These developments suggest Pharming is strategically poised to leverage scientific advances into commercial success, despite current unprofitability and market challenges.
Dive into the specifics of Pharming Group here with our thorough health report.
Assess Pharming Group's past performance with our detailed historical performance reports.
BioInvent International
Simply Wall St Growth Rating: ★★★★★☆
Overview: BioInvent International AB (publ) is a clinical-stage company focused on discovering and developing immuno-modulatory antibodies for cancer treatment, with a market cap of approximately SEK2.64 billion.
Operations: The company generates revenue primarily from developing antibody-based drugs, amounting to SEK60.80 million.
BioInvent International is making significant strides in the biotech sector, particularly with its innovative BI-1808 treatment for cutaneous T-cell lymphoma (CTCL), demonstrating a 100% disease control rate in recent trials. This promising performance is underpinned by a robust annual revenue growth forecast of 76.6% and an earnings growth projection of 91.77%. With R&D expenses aligned to propel future innovations, BioInvent not only surpasses the Swedish market's growth rate of 5.2% but also outpaces biotech industry norms, positioning it well for upcoming profitability within three years.
Click here and access our complete health analysis report to understand the dynamics of BioInvent International.
Gain insights into BioInvent International's past trends and performance with our Past report.
Bonesupport Holding
Simply Wall St Growth Rating: ★★★★★★
Overview: Bonesupport Holding AB (publ) is an orthobiologics company that specializes in developing and selling injectable bio-ceramic bone graft substitutes across Europe, North America, and other international markets, with a market cap of SEK21.76 billion.
Operations: Bonesupport Holding AB generates revenue primarily from its pharmaceuticals segment, amounting to SEK1.06 billion. The company focuses on the development and sale of injectable bio-ceramic bone graft substitutes across various regions, including Europe and North America.
Bonesupport Holding's recent financial performance underscores its potential within the European tech landscape, with a notable increase in Q2 sales to SEK 284.43 million from SEK 219.8 million the previous year, and net income more than doubling to SEK 53.07 million. This growth trajectory is complemented by an ambitious R&D strategy, critical for maintaining technological leadership and competitiveness. The company's robust revenue growth rate of 24% annually outpaces the broader Swedish market's growth of 5.2%, positioning it well for sustained advancements in its sector. Additionally, with earnings expected to surge by 62.3% annually, Bonesupport is poised to capitalize on expanding market opportunities while enhancing shareholder value through strategic reinvestments in innovation and market expansion initiatives.
Take a closer look at Bonesupport Holding's potential here in our health report.
Review our historical performance report to gain insights into Bonesupport Holding's's past performance.
Seize The Opportunity
Dive into all 52 of the European High Growth Tech and AI Stocks we have identified here.
Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Ready For A Different Approach?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTAM:PHARM OM:BINV and OM:BONEX.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Wall Street's Wild Rally: Why No One Cares About Tariffs Anymore
Investors are in full-on risk modeand they're not waiting around to see how the Trump tariffs play out. From small caps to crypto, riskier corners of the market are lighting up as bets on a Federal Reserve rate cut heat up. The S&P 500 (SPY) is up nearly 30% from its April lows, with Tesla (NASDAQ:TSLA) and other megacap techs carrying most of the load. According to Deutsche Bank, just a handful of tech giants were responsible for 90% of the index's Q2 earnings growth. The Russell 2000 is climbing for the fourth straight month, emerging-market stocks are catching bids, and even speculative European bank bonds are finding buyers. The fear? Gone. Volatility measures like the VIX and MOVE indexes are plumbing their lowest levels in months. Traders are now pricing in a nearly 90% chance the Fed cuts rates in September, with some even betting on a 50-basis-point move. Treasury Secretary Scott Bessent added fuel to that fire, saying rates should probably be 150 to 175 basis points lower. The market has latched onto that narrative. Even currency volatility has dropped to its lowest in a year. All the while, the economic backdrop remains soft: labor market data isn't running hot, inflation came in as expected, and for now, that's enough. The mood is surprisingly bullishit's almost like what tariffs, who cares?' said Neil Birrell, CIO at Premier Miton. That detachment from reality? It's workingat least for now. But not everyone's ready to join the parade. It's very expensive right now to be bearish, said UBS O'Connor's Bernard Ahkong, who still sees plenty of risks lurking in the background. Bloomberg's Mark Cudmore warned that rising long-end yields or another Trump curveball could snap the rally. Still, Wall Street strategistssome of whom had slashed targets back in Aprilare now raising their outlooks. Citigroup's Scott Chronert even bumped up his year-end S&P 500 target, betting that potential tax cuts could outweigh tariff impacts. For now, the market's not trading fearit's trading FOMO. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
JD.com to Acquire European Retailer CECONOMY in $2.B Takeover Bid
Inc. (NASDAQ:JD) is one of the best upside stocks to invest in now. On July 30, announced a decision to make a voluntary public takeover offer for all shares of CECONOMY AG. CECONOMY is the parent company of European consumer electronics retailers MediaMarkt and Saturn. The offer is being made through a wholly-owned subsidiary, called JINGDONG Holding Germany GmbH (the Bidder), for a cash consideration of EUR 4.60 per share. The Bidder and CECONOMY have signed an investment agreement related to the takeover offer and their future cooperation. The Bidder also has agreements with several CECONOMY shareholders, who have irrevocably committed to accept the offer for a total of 31.7% of the shares. This includes a 3.81% stake from CECONOMY's largest shareholder group, Convergenta Invest GmbH. A wide and imposing view of a supply chain distribution center, illustrating the company's technology capabilities. Post-takeover, Convergenta will hold 25.35% of the CECONOMY shares. This secures a combined shareholding of 57.1% for future partners and the company itself before the offer's launch. CECONOMY's Supervisory Board and Management Board are in full support of the takeover. plans to contribute its advanced technology, e-commerce expertise, and logistics capabilities to strengthen CECONOMY's business, which currently operates over 1,000 retail stores in 11 countries. Inc. (NASDAQ:JD) is a supply chain-based technology and service provider in the People's Republic of China. It operates through three segments: JD Retail, JD Logistics, and New Businesses. While we acknowledge the potential of JD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
CNET
14 minutes ago
- CNET
New Study Shows Smartwatch Stress Sensors Have No Idea What They're Doing
You might want to think twice before you put a lot of stock in the latest stress charts from your fitness wearable. A recent study from the Netherlands' Leiden University, published in the Journal of Psychopathology and Clinical Science, has found that when smartwatches and similar devices record readings on stress, fatigue, or sleep, they're frequently getting it wrong. Researchers studied 800 young adults using the same Garmin Vivosmart 4 smartwatch model. They compared the data the smartwatches produced with the reports that the users created four times per day about how sleepy or stressed they were feeling. Lead author and associate professor Eiko Fried said the correlation between the wearable data and the user-created data was, "basically zero." A representative for Garmin did not immediately respond to a request for comment. Stressed or sex? Your watch doesn't know So why do wearables like fitness smartwatches get it so wrong? Their sensors are fairly limited in what they can do. Watches like these need to be worn correctly at all times (a loose or tight watch may give poor readings, for example), and they typically use basic information like pulse rate and movement to make guesses about health. Those guesses don't always reflect real-world scenarios. A wearable may identify high stress when the real cause of the change was a workout, excitement over good news, or sex. There are so many potential alternatives to stress or fatigue that the watches in the study never really got it right -- and the devices sometimes guessed the complete opposite emotional state from what users recorded. The Dutch study did note that Garmin's Body Battery readings, which specifically measure physical fatigue, were more reliable than stress indicators, but still inaccurate. And sleep sensing performed the best of them all, with Garmin watches showing a two-thirds chance of noting the differences between a good night's sleep and a bad one. It's also worth noting that smartwatch sensors can become more accurate as technology improves. It would be interesting to run a similar study with the much newer Garmin Vivosmart 5 to see if anything has improved, as well as see if other models like the latest versions of the Apple Watch have similar accuracy results.
